Compare NRG Energy Inc (NRG) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Sana Biotechnology Inc — how do they compare? NRG Energy Inc trades at $107.97 (market cap $22.35B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: NRG Energy Inc is far larger — about 26.7× Sana Biotechnology Inc's market cap, and NRG Energy Inc pays a 1.79% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 63 Days and Sana Biotechnology Inc for 23 Days on average.
| NRG | SANA | |
|---|---|---|
Market Cap | $22.35B | $836.71M |
Volume | 5,011,942 | 4,507,444 |
Sector | Utilities | Health |
52-Week High | $184.03 | $5.92 |
52-Week Low | $95.23 | $2.68 |
Typical Hold Time | 63 Days | 23 Days |
Enterprise Value | $46.30B | $749.96M |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $106.32, down 2.11% today, with a bullish technical signal and strong analyst support. The stock shows mixed earnings performance with recent misses but maintains solid fundamentals including $30.71B revenue and 2.56% net margin. Recent developments include a 1.2 GW Texas data center power project and potential acquisition of a West Virginia coal plant, positioning for growth in energy infrastructure.
Outlook remains positive with 70% analyst buy ratings and $202.90 consensus price target representing 91% upside. Key risks include execution of major capital projects, debt levels at 56.42% of assets, and energy market volatility. The dividend yield of approximately 1.6% provides income support while growth initiatives drive long-term potential.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
